Voranigo
What Voranigo is used for
Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Voranigo
- Active substance
- vorasidenib
- Disease area
- Oligodendroglioma; Astrocytoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XM04
- Marketing authorisation holder
- Les Laboratoires Servier
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Voranigo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voranigo used for?
Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1).
What is the active substance in Voranigo?
Voranigo contains vorasidenib.
Who makes Voranigo?
The EU marketing authorisation holder is Les Laboratoires Servier.
Is Voranigo an orphan medicine?
Yes. Voranigo is designated an orphan medicine in the EU, for a rare disease (Oligodendroglioma; Astrocytoma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU